Lazertinib and Tagrisso go head to head

Astrazeneca’s Tagrisso has cemented its status as the most successful targeted lung cancer drug of recent times, but a challenger is emerging. Johnson & Johnson’s Mariposa study, pitting lazertinib head to head against Tagrisso, should read out this year.